XXI Wealth LLC’s Biogen BIIB Stock Holding History

XXI Wealth LLC’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$778K	Sell	3,603 -48	-1%	-$9.18K	0.36%	71
2026 Q1	$669K	Buy	3,651 +1,136	+45%	+$209K	0.38%	75
2025 Q4	$443K	Buy	+2,515	New	+$411K	0.27%	98

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

XXI Wealth LLC's BIIB Position: Q2 2026 in Review

XXI Wealth LLC reduced its Biogen (BIIB) stake by 1.3% in Q2 2026, selling an estimated $9.18K and leaving 3,603 shares worth $778K. The position accounts for 0.36% of the portfolio, ranked #71.

XXI Wealth LLC first reported a position in BIIB in Q4 2025 and has held it in 3 quarters since. 1,041 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

XXI Wealth LLC held 3,603 shares of Biogen worth $778K as of Q2 2026.
XXI Wealth LLC sold 48 Biogen shares in Q2 2026, an estimated $9.18K.
Biogen made up 0.36% of XXI Wealth LLC's portfolio in Q2 2026, its #71 holding.
XXI Wealth LLC first reported a position in Biogen in Q4 2025 and has held it in 3 quarters since.
1,041 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on XXI Wealth LLC's 13F filing for Q2 2026, filed 14 Aug 2026.